Yonhap Infomax NewsApr 24, 2025
Nomura maintains positive outlook on Samsung Biologics, citing potential 31% stock price increase driven by CMO growth, biosimilar sales, and U.S. Biosecurity Act benefits
#YonhapInfomax #SamsungBiologics #Nomura #CMOBusiness #Biosimilars #USBiosecurityAct #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=60169
Nomura - 'Samsung Biologics Stock Price Could Rise 31%'

Nomura maintains positive outlook on Samsung Biologics, citing potential 31% stock price increase driven by CMO growth, biosimilar sales, and U.S. Biosecurity Act benefits

Yonhap Infomax